1-14 of 14
Vijay Reddy, MD
Close
Sort by
Journal Articles

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Patrick J. Stiff, MD, Edward Agura, MD, Mark Litzow, MD, Ben Tomlinson, MD, Hannah K. Choe, MD, Sunil Abhyankar, MD, Stuart Seropian, MD, George L. Chen, MD, Parameswaran Hari, MBBS, MD, Zaid S. Al-Kadhimi, MD, James M. Foran, MD, Johnnie Orozco, MD, Koen Van Besien, MD PhD, Mitchell Sabloff, MD, Partow Kebriaei, MD, Moshe Yair Levy, MD, Hillard M Lazarus, MD, Sergio A Giralt, MD, Mark S. Berger, MD, Vijay Reddy, MD PhD, John M. Pagel, MD PhD DSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 5642.
https://doi.org/10.1182/blood-2019-122776
Published: 2019
Journal Articles

Feasibility of Administering Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] for Re-Induction and Targeted Conditioning in Older Patients with Active, Relapsed or Refractory AML without Lead-Lined Rooms: Sierra Trial Experience at MSKCC

Bae P Chu, MPH, Neeta Pandit-Taskar, MD, Boglarka Gyurkocza, MD, Qing Liang, PhD, Daniel Miodownik, MPH, Vijay Reddy, MD PhD, Mark S. Berger, MD, Lawrence T. Dauer, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5839.
https://doi.org/10.1182/blood-2019-131230
Published: 2019
Journal Articles

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

Rajneesh Nath, MD, Eileen M Geoghegan, Matthew L. Ulrickson, MD, Jennifer A Spross, MA, Renee H Lichtenstein, BA, Sandy Konerth, MS, Darrell R. Fisher, PhD, Qing Liang, PhD, Dale Ludwig, PhD BS, Vijay Reddy, MD PhD, Mark S. Berger, MD, Boglarka Gyurkocza, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1958.
https://doi.org/10.1182/blood-2019-128838
Published: 2019
Journal Articles

Preclinical Development of an Actinium-225-Labeled Antibody Radio-Conjugate Directed Against CD45 for Targeted Conditioning and Radioimmunotherapy

Dale Ludwig, PhD BS, Ruth Bryan, Wojciech Dawicki, PhD, Eileen M Geoghegan, Qing Liang, PhD, Sandesh Seth, MS, MBA, Mamata Gokhale, Mark S. Berger, MD, Vijay Reddy, MD PhD, Ravendra Garg, Kevin Allen, PhD, Ekaterina Dadachova
Journal: Blood
Blood (2019) 134 (Supplement_1): 5601.
https://doi.org/10.1182/blood-2019-128678
Published: 2019
Journal Articles

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Yong Mun, PhD, Neil E. Kay, MD, Tait D. Shanafelt, MD, Kari G. Chaffee, MS, Richard R. Furman, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jeff Sharman, MD, John F. Seymour, MBBS, PhD, Asher A. Chanan-Khan, MD, John C. Byrd, MD, Jeffrey A. Jones, MD MPH, Lucille A. Ferrante, MD, Lyndah K. Dreiling, MD, Mehrdad Mobasher, MD MPH, Thomas Stark, MD PhD, Vijay Reddy, MD PhD, Angela J. Howes, BSc, PhD, Danelle James, MD MAS, Pankaj Bhargava, MD, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4394.
https://doi.org/10.1182/blood-2018-99-112989
Published: 2018
Journal Articles

Targeted Conditioning of Iomab-B ( 131 I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial

Edward Agura, MD, Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Mark R. Litzow, MD, Benjamin K. Tomlinson, MD, Sunil Abhyankar, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Hannah K. Choe, MD, Partow Kebriaei, MD, James M. Foran, MD, George Chen, MD, Moshe Yair Levy, MD, Hillard M Lazarus, MD, Sergio Giralt, MD, Mark S. Berger, MD, Vijay Reddy, MD PhD, John M. Pagel, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1017.
https://doi.org/10.1182/blood-2018-99-111914
Published: 2018
Journal Articles

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

Jennifer R. Brown, MD PhD, Javid Moslehi, MD, Michael S. Ewer, MD MPH, JD, Susan M. O'Brien, MD, Paolo Ghia, MD PhD, Florence Cymbalista, MD, Tait D. Shanafelt, MD, Graeme Fraser, MD, Simon Rule, MD, Steven E. Coutre, MD, Marie-Sarah Dilhuydy, MD, Paula Cramer, MD, Ulrich Jaeger, MD, Martin Dreyling, MD, John C. Byrd, MD, Steven Treon, MD PhD, Emily Liu, Stephen Chang, PhD, Amulya Bista, Rama Vempati, Lisa Boornazian, BSN, Rudolph Valentino, PharmD, Vijay Reddy, MD PhD, Michelle Mahler, MD, Huiying Yang, MD PhD, Jan A. Burger, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1743.
https://doi.org/10.1182/blood.V130.Suppl_1.1743.1743
Published: 2017
Journal Articles

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Jacob D. Soumerai, MD, Ai Ni, PhD, Mohamed Darif, PhD, Anil Londhe, PhD, Guan Xing, PhD, Julie Huang, PhD, Ming Lin, PhD, John C. Byrd, MD, Asher A. Chanan-Khan, MD, Richard R. Furman, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Jeffrey Jones, MD, Jeffrey P. Sharman, MD, Lucille Ferrante, MD, Vijay Reddy, MD PhD, Lyndah K. Dreiling, MD, Henry Adewoye, MD, Ronald Dubowy, MD, Angela Howes, PhD, Danelle F. James, MD MAS, Andrew D. Zelenetz, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4303.
https://doi.org/10.1182/blood.V130.Suppl_1.4303.4303
Published: 2017
Journal Articles

Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Peter Martin, MD, Andre Goy, MD, Radhakrishnan Ramchandren, MD, Lucille Ferrante, MD, Vijay Reddy, MD PhD, Anil Londhe, Mark Wildgust, Tracy McGowan, MD, Nancy L Bartlett, MD
Journal: Blood
Blood (2014) 124 (21): 4461.
https://doi.org/10.1182/blood.V124.21.4461.4461
Published: 2014
Journal Articles

Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America

Christopher R. Flowers, MD, Michael Lill, M.D., Luciano J Costa, MD, PhD, Tsiporah B. Shore, William Vaughan, MD, Michael Craig, MD, Cesar O. Freytes, MD, Thomas C. Shea, M.D., Mitchell E. Horwitz, MD, Joseph W. Fay, MD, Shin Mineishi, MD, Damiano Rondelli, MD, James Mason, MD, Vijay Reddy, MD, PhD, Ira Braunschweig, MD, Weiyun Ai, MD, PhD, Elizabeth Armstrong, MS, Angela Smith, MS, PA, Cathy Zhao, PhD, Agnes Elekes, MD, Kazunobu Kato, MD, PhD, Edmund K. Waller, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 768.
https://doi.org/10.1182/blood.V122.21.768.768
Published: 2013
Journal Articles

Amino Acid Substitution At Peptide-Binding Pockets of HLA Class I Molecules Adversely Impacts Hematopoietic Cell Transplantation Outcomes

Joseph Pidala, MD, MS, Tao Wang, PhD, Michael D Haagenson, MS, Stephen Spellman, MBS, Medhat Askar, MD, PhD, Minoo Battiwalla, MD, MS, Lee Ann Baxter-Lowe, PhD, Menachem Bitan, MD, PhD, Marcelo Fernandez-Vina, PhD, Manish Gandhi, MD, Ann A. Jakubowski, MD, PhD, Martin Maiers, PhD, Susana R. Marino, MD, PhD, Steven GE Marsh, BSc, PhD, ARCS, Machteld Oudshoorn, PhD, Jeanne Palmer, MD, Vinod K. Prasad, MBBS, MD, MRCP, Vijay Reddy, MD, PhD, Olle Ringden, MD, PhD, Wael Saber, MD, MS, Stella Santarone, MD, Kirk R. Schultz, MD, Michelle Setterholm, Elizabeth Trachtenberg, Vicky Turner, PhD, D(ABHI), Ann Woolfrey, MD, Stephanie J. Lee, MD, MPH, Claudio Anasetti, MD
Journal: Blood
Blood (2012) 120 (21): 467.
https://doi.org/10.1182/blood.V120.21.467.467
Published: 2012
Journal Articles

A Pilot Trial of Two Dose Levels of Rabbit Antithymocyte Globulin, (rATG), Thymoglobulin, as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor Stem Cell Transplant (SCT) with Cyclosporine (CsA) as Graft Versus Host Disease (GvHD) Prophylaxis.

Kenneth B. Miller, MD, Nelson J. Chao, MD, Hans A. Messner, MD,PhD, Steven C. Goldstein, MD, Vijay Reddy, MD,PhD, William Vaughan, MD, Steven Devine, MD, Scott D. Rowley, MD, Ned Waller, MD,PhD, Marcel Devetten, MD, Gary J. Schiller, MD
Journal: Blood
Blood (2006) 108 (11): 5369.
https://doi.org/10.1182/blood.V108.11.5369.5369
Published: 2006
Journal Articles

A Randomized Single−Blind Study of Extracorporeal Photopheresis with UVADEX® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD.

Mary E.D. Flowers, MD, Koen Van Besien, MD, Jane Apperley, MD, Andrea Bacigalupo, MD, Ahmet Elmaagacli, MD, Andrew Grigg, MD, Hans-Jochem Kolb, MD, Luis Fernando Bouzas, MD, Mauricette Michallet, MD, Vijay Reddy, MD, Jim Wang, MD, Paul Williamson, MD, Robert Knobler, MD, Hildegard Greinix, MD
Journal: Blood
Blood (2006) 108 (11): 758.
https://doi.org/10.1182/blood.V108.11.758.758
Published: 2006
Journal Articles

High Levels of Interleukin-12 Are Associated with Reduced Incidence of Relapse and Death without Increasing Acute Graft-Versus-Host Disease (AGVHD) after Allogeneic Stem Cell Transplantation (SCT).

Vijay Reddy, MD, PhD, Andrew G. Winer, Erika Eksioglu, Jeffery Levine, Herwig-Ulf Meier-Kriesche, MD, Jesse Schold, MStat, Harvey Mossak, John R. Wingard, MD
Journal: Blood
Blood (2004) 104 (11): 295.
https://doi.org/10.1182/blood.V104.11.295.295
Published: 2004